Pharmacology of Combined Amiodarone Hydrochloride and Ranolazine Therapy in Atrial Fibrillation

Abstract

This review article presents the pharmacology of combined Amiodarone Hydrochloride and Ranolazine therapy specialy in Atrial Fibrillation. Amiodarone Hydrochloride is Anti Arrhythmic agent. Ranolazine is a Anti Anginal agent. The Antianginal agent was used in Ischaemia. Amiodarone Hydrochloride is Antiarrhythmic agent and use in Arrhythmia and Atrial fibrillation. If Amiodarone Hydrochloride is administered in large quantities, the condition of patient become worse by occurrence of adverse effect of Thyroid toxicity due to presence of Iodine moiety in Amiodarone. The use of Ranolazine in combination with Amiodarone Hydrochloride has been proved to provide beneficial effect in Atrial Fibrillation. The combination therapy has fewer adverse effect. The mechanism of Amiodarone Hydrochloride and Ranolazine is quite different. Amiodarone Hydrochloride inhibit potassium channel and inactivated-state blocker of cardiac sodium channel while Ranolazine inhibit late inward sodium current(INa) in cardiac cell and activated-state blocker of cardiac sodium channel. The combination of both have decrease dose dependent side effect of Amiodarone Hydrochloride. Both the drugs were approved by US government and has been used in Atrial Fibrillation in US. The main objective of this review article is to provide pharmacological information of combined therapy of Amiodarone Hydrochloride and Ranolazine to researcher in development of combined dosage form of this.